Nimbus Announces Change to Business Board
News Nov 22, 2005
Nimbus Biotechnology has reported a change to the company’s Supervisory Board. Professor Axel Kleemann, formerly executive board member of Asta Medica AG has been appointed as a new member and chairman of the Supervisory Board.
Professor Thomas Bayerl, Dr. Rainer Strohmenger (Wellington Partners Venture Capital GmbH, Germany), Jack Griffin and Mario Ober (CFH, Germany) continue to be board members.
Nimbus Biotechnology thanks Werner Zollner (Seed GmbH, Germany) for his former work and support in this position.
Wolfgang Lerch, CEO of Nimbus Biotechnology, stated, "The appointment of Professor Axel Kleemann is a very special opportunity for Nimbus Biotechnology."
"With his expertise we will strengthen our mission to support our customers with cutting-edge tools."
"We will come closer to developing modern tools for all stages of drug discovery. All employees of the company wish him success for his work."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018